Skin Barrier and Immune Dysregulation in Atopic Dermatitis: An Evolving Story with Important Clinical Implications

被引:139
作者
Czarnowicki, Tali [1 ,2 ]
Krueger, James G. [1 ,2 ]
Guttman-Yassky, Emma [1 ,3 ]
机构
[1] Rockefeller Univ, Invest Dermatol Lab, New York, NY 10021 USA
[2] Rockefeller Univ, Ctr Clin & Translat Sci, New York, NY 10021 USA
[3] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY 10029 USA
关键词
Atopic dermatitis; Microbiome; Immune dysregulation; Skin barrier; Proactive treatment; Residual disease genomic profile; Intrinsic atopic dermatitis; Extrinsic atopic dermatitis; STAPHYLOCOCCUS-AUREUS COLONIZATION; THYMIC STROMAL LYMPHOPOIETIN; EPIDERMAL LANGERHANS CELLS; GENE-EXPRESSION; T-CELLS; BETA-DEFENSIN-2; EXPRESSION; FLUTICASONE PROPIONATE; FILAGGRIN MUTATIONS; PROACTIVE THERAPY; DENDRITIC CELLS;
D O I
10.1016/j.jaip.2014.03.006
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Atopic dermatitis is the most common chronic inflammatory skin disease. Its pathogenesis combines barrier defects, immune dysregulation, and increased skin infections; however, the relative contribution of each of these components is yet to be determined. Uninvolved atopic dermatitis skin also displays broad immune and barrier abnormalities, which highlights a role for proactive treatment strategy. The residual disease genomic profile that accompanies clinical resolution provides further support for proactive treatment approaches. Although intrinsic and extrinsic atopic dermatitis subtypes share a common clinical phenotype, they show some important differences in their Th22/ Th17 cytokine profile, which opens the door for personalized specific therapeutics for each disease category. (C) 2014 American Academy of Allergy, Asthma & Immunology
引用
收藏
页码:371 / 379
页数:9
相关论文
共 137 条
  • [1] Staphylococcal-mediated worsening of atopic dermatitis: many players involved
    Agner, T.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2010, 163 (06) : 1147 - 1147
  • [2] Immunological differences between intrinsic and extrinsic types of atopic dermatitis
    Akdis, CA
    Akdis, M
    [J]. CLINICAL AND EXPERIMENTAL ALLERGY, 2003, 33 (12) : 1618 - 1621
  • [3] Akdis M, 1997, J IMMUNOL, V159, P4611
  • [4] Serum IgE autoantibodies target keratinocytes in patients with atopic dermatitis
    Altrichter, Sabine
    Kriehuber, Ernst
    Moser, Julia
    Valenta, Rudolf
    Kopp, Tamara
    Stingl, Georg
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2008, 128 (09) : 2232 - 2239
  • [5] Anti-IgE - emerging opportunities for Omalizumab
    Babu, K. Suresh
    Polosa, Riccardo
    Morjaria, Jaymin B.
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2013, 13 (05) : 765 - 777
  • [6] An update on the genetics of atopic dermatitis: Scratching the surface in 2009
    Barnes, Kathleen C.
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2010, 125 (01) : 16 - 29
  • [7] Barnes KC, 2010, J ALLERGY CLIN IMMUN, V125, p[16, e1]
  • [8] Interventions to reduce Staphylococcus aureus in the management of atopic eczema: an updated Cochrane review
    Bath-Hextall, F. J.
    Birnie, A. J.
    Ravenscroft, J. C.
    Williams, H. C.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2010, 163 (01) : 12 - 26
  • [9] Toward a major risk factor for atopic eczema:: Meta-analysis of filaggrin polymorphism data
    Baurecht, Hansjoerg
    Irvine, Alan D.
    Novak, Natalija
    Illig, Thomas
    Buehler, Bettina
    Ring, Johannes
    Wagenpfeil, Stefan
    Weidinger, Stephan
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2007, 120 (06) : 1406 - 1412
  • [10] A retrospective case series review of the peroxisome proliferator-activated receptor ligand rosiglitazone in the treatment of atopic dermatitis
    Behshad, Ramona
    Cooper, Kevin D.
    Korman, Neil J.
    [J]. ARCHIVES OF DERMATOLOGY, 2008, 144 (01) : 84 - 88